A study conducted by University of Cambridge researchers on mice showed the existing drugs- Trazodone and DBM to show positive impact on tau affected brain cells. These drugs prevented the death of brain cells and the mice also improved in memory tests. However, Trazaodone usage can result in side effects, including drowsiness and possibly some increased risk of falls.
Tauopathies are neurodegenerative diseases, characterized by the build up of tangled proteins such as tau. While the therapy market is still in infancy, companies are currently focusing on trials of five major types-
– progressive supranuclear palsy
– corticobasal degeneration
– Frontotemporal dementia (bvFTD)
– FTD with parkinsonism-17
– chronic traumatic encephalopathy
To estimate the revenue potential and design your investments in trials of global tauopahty therapeutics and to understand progress and success/failure of different pipeline products on tauopathies, please visit the following link-
In addition to details of different products in pipeline, the research work focuses on the impact of the recently launched trials/ interventions in the US and global markets. Further, strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications are also discussed.